Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.
Stomach Neoplasms|Gastric Cancer|Linitis Plastica of Stomach
DRUG: Tislelizumab|DRUG: Oxaliplatin|DRUG: S-1|DRUG: Capecitabine
MPR, Major pathologic response, defined as less than 10% residual tumor following neoadjuvant therapy, up to 2 years
Adverse Events, up to 2 years|Incidence of surgical complications, up to 2 years|Rate of R0 resection, up to 2 years|OS, 3-year overal survival, up to 5 years|DFS, 3-year disease-free survival, up to 5 years
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.